


Trend of OPDIVO

OPDIVO Sales Trend by Each Cancer




Progress Status of Key Indications (Apr–Dec 2025)

- **GC** : Progressed as per revised plan despite impact of competing products
- **NSCLC** : New prescription share in the PD-L1 negative segment is growing, but has not reached the plan; further activities are being strengthened to further expansion
- **ESC** : Although new competing products have entered the market, new prescription share increased and progress is on track
- **HC / CRC** : New prescription share remains steady

The Result of Clinical Trial - NSCLC 1L (PD-L1 negative) -

CheckMate 9LA Trial



OPDIVO + YERVOY + Chemo

Five-year overall survival rates


22%

Six-year overall survival rates

20%

Carbone DP, et al. ESMO Open. 2025 Jun;10(6):105123

CheckMate 227 Trial



OPDIVO + YERVOY

Five-year overall survival rates


19%

Six-year overall survival rates

16%

Suresh S. Ramalingam, et al. WCLC2023#OA14.03

Prescription Ratio in Patients Newly Treated* for 1L NSCLC



*Patients starting 1L treatment within the last 1 month (Except Driver Mutation)

Source: Primary research results
(Nov 2020-Oct 2025: n=167-245)